Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01258530
NCT01258530CompletedPhase 1

A Randomized, Open-label, Single-Dose, Two-Period, Crossover Study to Evaluate the Bioequivalence of Over-encapsulated Oseltamivir Capsules to Marketed Oseltamivir Capsules in Healthy Volunteers

GlaxoSmithKline1 site in 1 country28 target enrollmentStarted: December 20, 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Completed
Enrollment
28
Locations
1
Primary Endpoint
Plasma oseltamivir carboxylate maximum observed concentration (Cmax)
Study OverviewStudy DesignEligibility CriteriaArms & InterventionsOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

This is a study in healthy adult volunteers to assess the bioequivalence of over-encapsulated oseltamivir capsules to commercially available oseltamivir capsules. Both formulations will be administered in the fasting state.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Crossover
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to 65 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • •AST, ALT, alkaline phosphatase and bilirubin greater than or equal to 1.5xULN (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%).
  • •Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and cardiac monitoring.
  • •Male or female between 18 and 65 years of age inclusive, at the time of signing the informed consent.
  • •A female subject is eligible to participate if she is of: Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female subjects must agree to use contraception until the follow-up visit.
  • •Body weight greater than or equal to 50 kg and BMI within the range 18.5 - 31.0 kg/m2 (inclusive).
  • •Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.

Exclusion Criteria

  • •A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
  • •Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • •A positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  • •A positive test for HIV antibody.
  • •History of regular alcohol consumption within 6 months of the study defined as: an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits.
  • •The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • •Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • •History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation.
  • •Where participation in the study would result in donation of blood or blood products in excess of 500 mL within a 56 day period.
  • •Pregnant females as determined by positive serum or urine hCG test at screening or prior to dosing.
  • •Lactating females.
  • •Unwillingness or inability to follow the procedures outlined in the protocol.
  • •Subject is mentally or legally incapacitated.
  • •History of sensitivity to heparin or heparin-induced thrombocytopenia.
  • •Urinary cotinine levels indicative of smoking or history of regular use of tobacco- or nicotine-containing products within 6 months prior to screening.
  • •Consumption of red wine, seville oranges, grapefruit or grapefruit juice from 7 days prior to the first dose of study medication.
  • •Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy, peptic ulceration, inflammatory bowel disease or pancreatitis should be excluded.
  • •The subject's systolic blood pressure is outside the range of 90-140 mmHg, or diastolic blood pressure is outside the range of 45-90 mmHg or heart rate is outside the range of 50-100 bpm for female subjects or 45-100 bpm for male subjects.
  • •Exclusion criteria for screening ECG (a single repeat is allowed for eligibility determination): Heart rate Males <45 and >100 bpm Females <50 and >100 bpm; PR Interval <120 and >220 msec; QRS duration <70 and >120 msec; QTc interval (Bazett) >450 msec.
  • •Evidence of previous myocardial infarction (Does not include ST segment changes associated with repolarization).
  • •Any conduction abnormality (including but not specific to left or right complete bundle branch block, AV block [2nd degree or higher], Wolf Parkinson White [WPW] syndrome, non-sustained or sustained ventricular tachycardia (greater than or equal to 3 consecutive ventricular ectopic beats).sinus pauses > 3 seconds, or other significant arrhythmia which, in the opinion of the principal investigator and GSK medical monitor, will interfere with the safety of the individual subject.

Arms & Interventions

Treatment B

Experimental

oseltamivir 75 mg (1 capsule)

Intervention: oseltamivir (Drug)

Treatment A

Experimental

Over-encapsulated oseltamivir 75 mg (1 capsule)

Intervention: over-encapsulated oseltamivir (Drug)

Outcomes

Primary Outcomes

Plasma oseltamivir carboxylate maximum observed concentration (Cmax)

Time Frame: 9 days

Plasma oseltamivir carboxylate area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity))

Time Frame: 9 days

Secondary Outcomes

  • Plasma oseltamivir AUC (0-infinity)(9 days)
  • Plasma oseltamivir AUC(0-t)(9 days)
  • Plasma oseltamivir t1/2(9 days)
  • Plasma oseltamivir carboxylate terminal phase half-life (t1/2)(9 days)
  • Plasma oseltamivir carboxylate area under the concentration-time curve from time zero (pre-dose) to the time of the last quantifiable concentration (AUC(0-t))(9 days)
  • Plasma oseltamivir carboxylate time of occurrence of Cmax (tmax)(9 days)
  • Plasma oseltamivir Cmax(9 days)
  • Plasma oseltamivir lag time before observation of drug concentrations in sampled matrix (tlag)(9 days)
  • Plasma oseltamivir tmax(9 days)
  • Safety and tolerability of all treatments, including number of subjects with adverse events assessment(4 weeks)
  • Safety and tolerability of all treatments, including number of subjects with concurrent medications(4 weeks)
  • Safety and tolerability of all treatments, change from baseline and number subjects with abnormal clinical safety laboratory data(4 weeks)
  • Safety and tolerability of all treatments, including change from baseline and number of subjects with abnormal ECG assessments(4 weeks)
  • Safety and tolerability of all treatments, including change from baseline and number of subjects with abnormal vital signs (blood pressure and heart rate) assessments(4 weeks)
  • Plasma oseltamivir carboxylate lag time before observation of drug concentrations in sampled matrix(tlag)(9 days)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
A Study Conducted in Healthy Subjects to Demonstrate Bioequivalence Between Ropinirole Prolonged Release Tablets Manufactured at Crawley and ArandaParkinson Disease
NCT01371682GlaxoSmithKline50
Completed
Phase 1
A Study to Evaluate the Bioequivalence of a Combined Formulated Tablet Compared With Maraviroc and Combivir™Infection, Human Immunodeficiency Virus I
NCT01597648GlaxoSmithKline42
Completed
Phase 1
Bioequivalence of Testosterone Reduced-size Patch Relative to the Testosterone Reference PatchHealthy
NCT00791856Warner Chilcott110
Completed
Phase 1
The Bioequivalence Study of Lamotrigine Dispersible/Chewable Tablets 5mg×5 Compared With Lamotrigine Compressed Tablet 25mg in Chinese Healthy Male SubjectsEpilepsy
NCT01879423GlaxoSmithKline24
Completed
Phase 1
Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy VolunteersHealthy
NCT05572281Vanda Pharmaceuticals36
A Study to Evaluate the Bioequivalence of... | Clinical Trial